Opinion|Videos|April 4, 2025
Implementation Barriers
Experts discuss the most significant barriers to continuous glucose monitoring (CGM) implementation encountered in their respective roles and how these barriers vary across different patient populations and care settings.
Advertisement
Episodes in this series
Video content above is prompted by the following:
What are the most significant barriers to CGM implementation you've encountered in your respective roles?
How do these barriers vary across different patient populations and care settings?
Advertisement
Related to this article
Initial frontal fibrosing alopecia treatment was largely similar in Black and White patients, though tetracycline use was higher in Black patients.
Telehealth surpasses out-of-state travel for abortion care in total-ban states in 2025, and a second study suggests telehealth and clinic patients differ.
Shields Health Solutions leaders say GLP-1 discontinuation is a support problem, not a medication problem, and pharmacist-led care can help close it.
Most Medicaid unwinding losses were procedural. mPulse's SriVani Ganti explains how plans can keep eligible members.
Youths with depression had about twice the odds of prescription drug misuse and 4 times the odds of use disorder, compared with peers without depression.
Advertisement
Advertisement
Trending on AJMC
1
HHS Draft Policy Eases Enforcement on 6 Compounded Peptides
2
5 Things to Know About HHS's Interim Peptide Compounding Policy
3
Four Major Idiopathic Pulmonary Fibrosis Advances From 2026
4
Experts Pitch National Risk Pool to Fund Gene Therapy Access
5